NovaBay Pharmaceuticals is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX™ family of products, led byAVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million. NovaBay is gaining market traction with AVENOVA through its 35-medical direct sales representatives under veteran leadership. AVENOVA is available for order in 90% of all pharmacies across the U.S. through distribution agreements with AmerisourceBergen, Cardinal Health and McKesson.
Products
5980 Horton Street, Suite 550,
Emeryville, CA
94608
× × × × × × ×
![Please login or create a free account to see this information.](data:image/png;base64,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)